Literature DB >> 2555923

A formalin-inactivated whole SIV vaccine confers protection in macaques.

M Murphey-Corb1, L N Martin, B Davison-Fairburn, R C Montelaro, M Miller, M West, S Ohkawa, G B Baskin, J Y Zhang, S D Putney.   

Abstract

A vaccine against human immunodeficiency virus (HIV) would be highly effective in stopping the acquired immunodeficiency syndrome (AIDS) epidemic. A comprehensive evaluation of potential vaccine methodologies can be made by means of the simian model for AIDS, which takes advantage of the similarities in viral composition and disease potential between simian immunodeficiency virus (SIV) infection of rhesus macaques and HIV infection in humans. Immunization with a formalin-inactivated whole SIV vaccine potentiated with either alum and the Syntex adjuvant threonyl muramyl dipeptide (MDP) or MDP alone resulted in the protection of eight of nine rhesus monkeys challenged with ten animal-infectious doses of pathogenic virus. These results demonstrate that a whole virus vaccine is highly effective in inducing immune responses that can protect against lentivirus infection and AIDS-like disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555923     DOI: 10.1126/science.2555923

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  95 in total

Review 1.  Strategies for an HIV vaccine.

Authors:  Norman L Letvin
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates.

Authors:  J L Spouge
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

3.  Sterile filtration of a parenteral emulsion.

Authors:  D M Lidgate; T Trattner; R M Shultz; R Maskiewicz
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

4.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

5.  HIV-1 vaccine development: progress and prospects.

Authors:  Anna R Thorner; Dan H Barouch
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

6.  Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.

Authors:  Todd M Allen; Peicheng Jing; Briana Calore; Helen Horton; David H O'Connor; Tomas Hanke; Marian Piekarczyk; Richard Ruddersdorf; Bianca R Mothé; Carol Emerson; Nancy Wilson; Jeffrey D Lifson; Igor M Belyakov; Jay A Berzofsky; Chenxi Wang; David B Allison; David C Montefiori; Ronald C Desrosiers; Steven Wolinsky; Kevin J Kunstman; John D Altman; Alessandro Sette; Andrew J McMichael; David I Watkins
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 7.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

8.  Cytoskeletal proteins bound to heat-shock protein 70 may elicit resistance to simian immunodeficiency virus infection of CD4(+) T cells.

Authors:  Lesley A Bergmeier; Kaboutar Babaahmady; Jeffrey Pido-Lopez; Kate J Heesom; Charles G Kelly; Thomas Lehner
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

9.  Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.

Authors:  L O Arthur; J W Bess; R G Urban; J L Strominger; W R Morton; D L Mann; L E Henderson; R E Benveniste
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

Authors:  J E Clements; R C Montelaro; M C Zink; A M Amedee; S Miller; A M Trichel; B Jagerski; D Hauer; L N Martin; R P Bohm
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.